Higher-educated people with Alzheimer’s disease (AD) can harbor greater neuropathologic burden than those with less education despite similar symptom severity. In a new study published in the journal Neurology, authors assessed whether this observation is also present in potential preclinical AD stages, namely in people with subjective cognitive decline, mild cognitive impairment and dementia. Data of the AMYPAD Diagnostic and Patient Management Study (DPMS) were used. The DPMS was a phase 4, multicenter, prospective randomized controlled study, which aimed testing the clinical utility of amyloid PET. Participants presented cognitive complaints and were recruited from 8 European memory clinics. 

Congratulations to all authors: Merle Hönig, Daniele Altomare, Camilla Caprioglio, Lyduine Collij, Frederik Barkhof,  Bart Van Berckel, Philip Scheltens, Gill Farrar, Mark R. Battle, Hendrik Theis, Kathrin Giehl, Gerard N. Bischof, , Valentina Garibotto, José Luis L. Molinuevo, Oriol Grau-Rivera, Julien Delrieu, Pierre Payoux, Jean Francois Demonet, Agneta K. Nordberg, Irina Savitcheva, Zuzana Walker, Paul Edison, Andrew W. Stephens, MD, Rossella Gismondi, Frank Jessen, Christopher J. Buckley, Juan Domingo Gispert, Giovanni B. Frisoni, and Alexander Drzezga, for the AMYPAD Consortium

You can read the article here: https://doi.org/10.1212/WNL.0000000000208053